Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine.
about
Immunological Evaluation of Recent MUC1 Glycopeptide Cancer VaccinesEntirely Carbohydrate-Based Vaccines: An Emerging Field for Specific and Selective Immune ResponsesSynthetic self-adjuvanting glycopeptide cancer vaccinesChallenges in Antibody Development against Tn and Sialyl-Tn AntigensStrategy for Designing a Synthetic Tumor Vaccine: Multi-Component, Multivalency and Antigen ModificationGlycotherapy: new advances inspire a reemergence of glycans in medicineNovel Immunotherapeutic Approaches for Head and Neck Squamous Cell CarcinomaTotal synthesis of glycosylated proteinsMolecular mimics of the tumour antigen MUC1Sialyl-tn in cancer: (how) did we miss the target?Synthesis and evaluation of monophosphoryl lipid A derivatives as fully synthetic self-adjuvanting glycoconjugate cancer vaccine carriersMUC1: a multifaceted oncoprotein with a key role in cancer progression.Immune and anticancer responses elicited by fully synthetic aberrantly glycosylated MUC1 tripartite vaccines modified by a TLR2 or TLR9 agonist.Altered Mucins (MUC) trafficking in benign and malignant conditions.Liposomes as vaccine delivery systems: a review of the recent advances.Carbohydrate antigen delivery by water soluble copolymers as potential anti-cancer vaccines.Analysis of carbohydrates and glycoconjugates by matrix-assisted laser desorption/ionization mass spectrometry: An update for 2011-2012.Cancer associated aberrant protein O-glycosylation can modify antigen processing and immune response.Synthesis of homogeneous MUC1 oligomers via a bi-directional ligation strategy.Glycan elongation beyond the mucin associated Tn antigen protects tumor cells from immune-mediated killing.Synthesis and biological evaluation of a novel MUC1 glycopeptide conjugate vaccine candidate comprising a 4'-deoxy-4'-fluoro-Thomsen-Friedenreich epitope.Genetically engineered mice as experimental tools to dissect the critical events in breast cancerAberrant glycosylation promotes lung cancer metastasis through adhesion to galectins in the metastatic nicheImmunotherapeutic approaches to ovarian cancer treatment.Single molecule study of heterotypic interactions between mucins possessing the Tn cancer antigen.A conjugate of octamer-binding transcription factor 4 and toll-like receptor 7 agonist prevents the growth and metastasis of testis embryonic carcinomaUp-regulation of C1GALT1 promotes breast cancer cell growth through MUC1-C signaling pathwayLinear synthesis and immunological properties of a fully synthetic vaccine candidate containing a sialylated MUC1 glycopeptide.Conjugation of toll-like receptor-7 agonist to gastric cancer antigen MG7-Ag exerts antitumor effects.Tecemotide: an antigen-specific cancer immunotherapy.Tumor-Associated Glycans and Immune SurveillanceMUC1 Vaccines, Comprised of Glycosylated or Non-Glycosylated Peptides or Tumor-Derived MUC1, Can Circumvent Immunoediting to Control Tumor Growth in MUC1 Transgenic Mice.Genetically engineered mucin mouse models for inflammation and cancer.Loss of Core 1-derived O-Glycans Decreases Breast Cancer Development in MiceTwo opposing roles of O-glycans in tumor metastasis.Microarray Analysis of Antibodies Induced with Synthetic Antitumor Vaccines: Specificity against Diverse Mucin Core Structures.Molecular basis of antibody binding to mucin glycopeptides in lung cancerCytotoxic T cell responses are enhanced by antigen design involving the presentation of MUC1 peptide on cholera toxin B subunitA Fully Synthetic Self-Adjuvanting Globo H-Based Vaccine Elicited Strong T Cell-Mediated Antitumor Immunity.Synthesis and immunological evaluation of a MUC1 glycopeptide incorporated into l-rhamnose displaying liposomes.
P2860
Q26740513-5EC49CD1-4E5E-45D4-B50E-2B5AD6B9E5ABQ26746887-F9C4009F-6F49-4EA4-89F1-A2494CEB361EQ26777837-5FBC19B4-7B5B-41E8-BAEC-BE3A9114FF34Q26798183-CECAFDAB-E3B7-407D-9BA6-8CA5D68B9282Q27001592-B52328CB-17E2-4E25-AD3C-B88ABD56CE0FQ27027997-BEFB4D70-A884-418B-9761-9BF7DD89F354Q28071998-53E21838-4037-4F42-8AED-5836E38E458BQ28083496-A6EA5F9F-0EBF-45BD-B160-2879F5EADD0AQ28485169-05519CA6-DE07-4C52-B830-60A45D5AC404Q33649572-49D2888E-672D-4464-88FD-0300F08660C2Q33819711-32A20556-7A7D-4182-8199-8672C77DEB84Q33880143-A86237C6-3977-4D3F-84FF-0CBA1DA439ADQ33961477-C36E6395-9C1C-4FAC-B0C8-E58837943224Q34365646-99343DF5-1D74-4D36-8C3B-F20C786A7BCBQ34418761-7332C423-19B9-4E4F-A8F0-BA8CE4802420Q34478719-E464B3D7-EDBF-4F40-94E8-85CE3DC59A46Q34489424-9292B404-A69B-4B61-A526-AECA81FABFC2Q34494018-727445C6-F224-494F-8DEA-072D23C99BF3Q34901076-C33A0D29-E6CD-4EAE-B50C-27ABBEF25E8EQ34988382-4408515F-F334-498C-80E2-E16E6B1D7453Q35030845-565B4042-80C2-4419-BDA1-3D7EABD208A8Q35146602-C082B8E0-BA04-4B24-AF94-C8BEF64459BDQ35201294-BB2E7A83-811C-4CAC-84A9-5031AD182281Q35213535-A0E7DF1D-B5D9-4082-AF17-C5FF039391B6Q35216220-BBBAF0B5-7C76-4095-8853-F6A30BB89C55Q35684190-599B3F3F-34DB-45C2-AC45-7D762D321B41Q35742481-2A3F0D8F-13F3-4D6B-8A67-8EAC8CF3EC3CQ35800918-61FB3B53-19CA-43F0-B396-C970DBAD9B7FQ35843039-66FCA9B3-0B8D-4847-86BD-AE1DCDFF4950Q35886761-4F937B0D-BF13-4300-8AF2-798931651D89Q35890610-0B9D1CE9-E373-4F0A-AE69-EC7D585DBBCBQ35898801-B96DB9E8-6200-499E-AB3D-9D27D16A1CD2Q35904634-810F2FBF-95F5-4F6F-B180-CC5FB93B6187Q35953085-73FD53C5-199C-45DC-B7CD-883D1E34FCB8Q35972468-37F90EA8-8AAC-461F-A16F-B988C4717DF1Q36221411-3754869D-82DF-4320-B197-4F3291A6056AQ36498123-95C776D1-21BA-42AF-B2E2-50E544975900Q36544143-23427490-A1FA-4962-A9CB-46482B1191F2Q36604334-120994D4-6FEA-43B4-8A1E-19BFDD53C96DQ36758192-98CBFFD0-E463-4810-A6E4-D0D1DB22FF54
P2860
Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Immune recognition of tumor-as ...... lated MUC1 tripartite vaccine.
@ast
Immune recognition of tumor-as ...... lated MUC1 tripartite vaccine.
@en
type
label
Immune recognition of tumor-as ...... lated MUC1 tripartite vaccine.
@ast
Immune recognition of tumor-as ...... lated MUC1 tripartite vaccine.
@en
prefLabel
Immune recognition of tumor-as ...... lated MUC1 tripartite vaccine.
@ast
Immune recognition of tumor-as ...... lated MUC1 tripartite vaccine.
@en
P2093
P2860
P50
P356
P1476
Immune recognition of tumor-as ...... lated MUC1 tripartite vaccine.
@en
P2093
Cathy S Madsen
Judy M Bradley
Latha B Pathangey
Pamela Thompson
Peter A Cohen
Sandra J Gendler
Therese Buskas
P2860
P304
P356
10.1073/PNAS.1115166109
P407
P577
2011-12-14T00:00:00Z